Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

JA Cauley, L Norton, ME Lippman, S Eckert… - Breast cancer research …, 2001 - Springer
Raloxifene, a selective estrogen receptor modulator approved for the prevention and
treatment of postmenopausal osteoporosis, has shown a significant reduction in breast …
被引用次数：962 相关文章

[引用][C] Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

JA CAULEY, L NORTON, JJ STEPAN… - Breast cancer …, 2001 - scholarship.miami.edu

[引用][C] Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

JA CAULEY, L NORTON, JJ STEPAN… - Breast cancer …, 2001 - pascal-francis.inist.fr
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year
results from the MORE trial CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

JA Cauley, L Norton, ME Lippman… - … Cancer Research and …, 2001 - search.proquest.com
Raloxifene, a selective estrogen receptor modulator approved for the prevention and
treatment of postmenopausal osteoporosis, has shown a significant reduction in breast …

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

JA Cauley, L Norton, ME Lippman, S Eckert… - Breast Cancer Research …, 2001 - infona.pl
Raloxifene, a selective estrogen receptor modulator approved for the prevention and
treatment of postmenopausal osteoporosis, has shown a significant reduction in breast …

[引用][C] Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

JA Cauley, L Norton, ME Lippman… - BREAST CANCER …, 2001 - research.unipd.it

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

JA Cauley, L Norton, ME Lippman, S Eckert… - … Cancer Research and …, 2001 - elibrary.ru
Raloxifene, a selective estrogen receptor modulator approved for the prevention and
treatment of postmenopausal osteoporosis, has shown a significant reduction in breast …

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene …

JA Cauley, L Norton, ME Lippman… - Breast cancer …, 2001 - pubmed.ncbi.nlm.nih.gov
Raloxifene, a selective estrogen receptor modulator approved for the prevention and
treatment of postmenopausal osteoporosis, has shown a significant reduction in breast …

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial

JA Cauley, L Norton… - Breast Cancer …, 2001 - mdanderson.elsevierpure.com
Raloxifene, a selective estrogen receptor modulator approved for the prevention and
treatment of postmenopausal osteoporosis, has shown a significant reduction in breast …

[引用][C] Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial

JA CAULEY, L NORTON, ME LIPPMAN… - Breast cancer research …, 2001 - Springer